Anti-tumor activity in pre-clinical models of SMARCA4-deficient tumors have recently been identified in CDK4/6, AURKA, ATR, and EZH2 inhibition; hence, promising results await through future trials on the use of these agents alone or in combination with ICIs [42]. This evidence concerns the gene SMARCA4 and neoplasm.